BIOAF - Bioasis Technologies Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.2192
+0.0056 (+2.65%)
At close: 1:01PM EDT
Stock chart is not supported by your current browser
Previous Close0.2136
Open0.1848
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.1848 - 0.2192
52 Week Range0.1848 - 0.4750
Volume8,500
Avg. Volume3,557
Market Cap12.438M
Beta (3Y Monthly)-0.96
PE Ratio (TTM)N/A
EPS (TTM)-0.0830
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Business Wire4 days ago

    Bioasis Announces Stock Option Grants

    TSX.V:BTI), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 ™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced that it has granted stock options to acquire a total of 1,576,240 common shares at a price of $0.27 per share to directors and officers of the company, including 510,000 options granted to Mario Saltarelli, who joined the board as a new director in May 2019 and 391,240 options granted to Deborah Rathjen, President & Chief Executive Officer, in lieu of cash compensation. The options granted to Dr. Rathjen are immediately exercisable, the options granted to Dr. Saltarelli vest over a period of 12 months from the date of grant and the rest of the options, all of which were issued to officers of the company, vest over a period of five years from the date of grant.

  • Business Wire26 days ago

    Bioasis Announces FDA Response to Pre-IND Submission

    OTCQB:BIOAF) (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced it had received feedback to its pre-Investigational New Drug (”IND”) submission to the U.S. Food and Drug Administration (“FDA”) regarding the planned development of xB3-001, the Company’s lead investigational candidate to treat brain cancer.

  • Business Wire27 days ago

    Bioasis Announces Allowances of Patent Applications in the U.S. and Europe Relating to xB3 Platform Technology and Key Therapeutic Indications

    OTCQB:BIOAF) (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 TM platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced that the U.S. Patent and Trademark Office (“USPTO”) and the European Patent Office (“EPO”) have issued allowances of patent applications relating to xB3 technology.

  • Business Wire2 months ago

    Bioasis Appoints Mario Saltarelli as Non-Executive Director of the Board of Directors

    TSX.V:BTI), ), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 TM platform technology for the delivery of therapeutics across the blood-brain barrier (the “BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced the appointment of Mario Saltarelli, M.D., Ph.D., as non-executive director of the Bioasis board of directors. Dr. Saltarelli served on Bioasis’ scientific advisory board (SAB) since June 2018.

  • Business Wire2 months ago

    Bioasis Announces Closing of Previously Disclosed Private Placement

    TSX.V:BTI), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 TM platform technology for the delivery of therapeutics across the blood-brain barrier (the “BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced the close of its previously announced private placement of units, (the “Units”) by issuing an aggregate of 4,588,978 Units at a price of C$0.28 per Unit, for gross proceeds of C$1,284,914. Each Unit consists of one common share of the Company (a “Common Share“) and one Common Share purchase warrant (each whole Common Share purchase warrant, a “Warrant“).

  • Business Wire2 months ago

    Bioasis Announces Private Placement

    TSX.V:BTI), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 ™ platform technology for the delivery of therapeutics across the blood-brain barrier (the “BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced that it intends to complete a non-brokered private placement of units (individually as “Unit” or collectively as the "Units") at a price of C$0.28 per Unit, for aggregate gross proceeds of approximately C$1,000,000 million. Each Unit will consist of one common share of the Company (a "Common Share") and one Common Share purchase warrant (each whole Common Share purchase warrant, a "Warrant"). Each Warrant entitles the registered holder to purchase one Common Share (a “Warrant Share”) at an exercise price of C$0.60 per Warrant Share for a period of 48 months from the date of closing of the private placement, subject to the terms and conditions set out in the Warrant.

  • Business Wire4 months ago

    Bioasis Technologies Inc. Announces Warrant Extension

    BIOASIS TECHNOLOGIES INC. , a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 TM platform technology for the delivery of therapeutics across the blood-brain barrier and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced that it has applied for approval from the TSX Venture ...

  • Business Wire4 months ago

    Bioasis Appoints Dr. Deborah Rathjen as President & Chief Executive Officer

    TSX.V:BTI), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 TM platform technology for the delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced that its board of directors has appointed Dr. Deborah A. Rathjen as president and chief executive officer. Dr. Rathjen, who is a member of the board of directors and has served as executive chair since December 10, 2018, replaces Dr. Mark Day, who has left the company, effective immediately.

  • Associated Press6 months ago

    BiOasis: Fiscal 3Q Earnings Snapshot

    The Guilford, Connecticut-based company said it had a loss of less than 1 cent on a per-share basis. The biotech drug developer posted revenue of $926,000 in the period. The company's shares closed at ...

  • Business Wire6 months ago

    Bioasis Announces Filing of Its Quarterly Financial Statements and MD&A for the Period Ending November 30, 2018

    BIOASIS TECHNOLOGIES INC. , a biopharmaceutical company developing its xB3 TM proprietary platform technology for the delivery of therapeutics across the blood-brain barrier and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced that it has filed its unaudited quarterly financial statements and management’s discussion ...

  • Business Wire6 months ago

    Bioasis Announces the Appointment of Christine Antalik as Chief Financial Officer

    OTCQB:BIOAF) (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 TM platform technology for the delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced the appointment of Christine Antalik as chief financial officer.

  • Business Wire6 months ago

    Bioasis Announces Agreement With Leading Pharmaceutical Company for Pre-Clinical Research Using the xB3 Platform Technology

    OTCQB:BIOAF) (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 TM platform technology for the delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced a joint research collaboration with a leading pharmaceutical company.

  • Business Wire7 months ago

    Bioasis to Present at Investor & Industry Conferences in January 2019

    Bioasis Technologies Inc.  , a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3™ platform t

  • Bioasis Appoints Dr. Deborah A. Rathjen as Executive Chair of the Board of Directors
    Business Wire7 months ago

    Bioasis Appoints Dr. Deborah A. Rathjen as Executive Chair of the Board of Directors

    OTCQB:BIOAF) (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 TM platform technology for the delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced the appointment of Deborah A. Rathjen, B.Sc.

  • Business Wire8 months ago

    Bioasis Announces Voting Results for 2018 Annual and Special Meeting

    OTCQB:BIOAF) (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 TM platform technology for the delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced the voting results from its Annual & Special Meeting held on Mon., Nov. 26, 2018 in Toronto, Ontario. All five (5) candidates nominated for election to the Bioasis board of directors and listed in the Company's Management Information Circular dated Oct. 25, 2018, being Deborah Ann Rathjen, B.Sc.

  • Business Wire8 months ago

    Bioasis Announces Positive Results from Peripheral Whole-Body PET/CT Scan Study in Non-Human Primates with Lead Investigational Candidate xB3-001™

    OTCQB:BIOAF) (the “Company”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 ™ platform technology for the delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced data using the Company’s lead investigational candidate xB3-001 in an advanced positron emission tomography and computed tomography (PET/CT) imaging study in non-human primates suggest selective peripheral distribution. The data also indicates penetration of the lymphatic system with xB3-001.

  • Associated Press9 months ago

    BiOasis: Fiscal 2Q Earnings Snapshot

    On a per-share basis, the Guilford, Connecticut-based company said it had a loss of 1 cent. The company's shares closed at 30 cents. A year ago, they were trading at 71 cents. _____ This story was generated ...

  • Business Wire9 months ago

    Bioasis Announces Filing of Its Quarterly Financial Statements and MD&A for the Period Ending August 31, 2018

    TSX.V:BTI), a biopharmaceutical company developing its xB3 TM proprietary platform technology for the delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced that it has filed its unaudited quarterly financial statements and management’s discussion and analysis for the period ended Aug. 31, 2018. All are available under the Company's profile on SEDAR at www.sedar.com and on the Company's website at www.bioasis.us/investors/.

  • Bioasis Announces xB3 ™ Platform Technology Licensing Agreement with Prothena
    Business Wire9 months ago

    Bioasis Announces xB3 ™ Platform Technology Licensing Agreement with Prothena

    OTCQB:BIOAF) (the “Company”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 ™ platform technology for the delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced it has entered into a licensing agreement with a subsidiary of Prothena Corporation plc) (“Prothena”), granting Prothena certain rights to use the xB3 platform technology for neuroscience targets. The agreement gives Prothena a worldwide, exclusive license to use the xB3 platform in connection with one undisclosed neurodegenerative disease target as well as a time-limited option for three additional neuroscience targets to be named by Prothena.

  • Business Wire10 months ago

    Bioasis Announces Investor Relations Service Agreement with Stern IR

    OTCQB:BIOAF), a biopharmaceutical company developing its proprietary xB3 ™ platform technology for the delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced it has engaged Stern Investor Relations, Inc. (“Stern IR”) to provide strategic advisory services, enhance and execute the Company’s investor relations program and support ongoing efforts to expand visibility within the North American investment community in compliance with regulatory guidelines. “In an increasingly complex and diverse marketplace, an effective investor relations program is essential to communicate our growth strategy, differentiate Bioasis in the eyes of investors and position our company for long-term success,” said Catherine London, executive vice president, investor relations and corporate communications, Bioasis.

  • Aeromics, Inc. Appoints Pharmaceutical and Biotech Veterans Mark Day, Ph.D. and Thomas Zindrick, J.D. to Its Board of Directors
    Business Wire11 months ago

    Aeromics, Inc. Appoints Pharmaceutical and Biotech Veterans Mark Day, Ph.D. and Thomas Zindrick, J.D. to Its Board of Directors

    Aeromics, Inc. (“Aeromics” or “the Company”), a privately-held, clinical-stage pharmaceutical company focused on controlling cerebral edema, or brain swelling, for people affected by disabling and life-threatening severe ischemic stroke, announced today the appointments of Mark Day, Ph.D. and Thomas Zindrick, J.D. to the Aeromics board of directors. “Mark and Tom bring extensive leadership and drug development experience to our board,” said Jeffrey P. Draime, chairman of the board, Aeromics.

  • Business Wire11 months ago

    Bioasis Announces Closing of Previously Disclosed Private Placement

    OTCQB:BIOAF) (“Bioasis” or the “Company”), a biopharmaceutical company developing its xB3 TM proprietary platform technology for the delivery of therapeutics across the blood-brain barrier (BBB) for the treatment of central nervous system (CNS) disorders, today announced the close of its previously announced private placement of units, (the “Units”) by issuing an aggregate of 1,762,179 Units at a price of C$0.552 per Unit, for gross proceeds of C$972,722.80. Each Unit consists of one common share of the Company (a "Common Share") and one Common Share purchase warrant (each whole Common Share purchase warrant, a "Warrant"). Each Warrant entitles the registered holder to purchase one Common Share (a “Warrant Share”) at an exercise price of C$0.69 per Warrant Share for a period of 60 months from the date of closing.

  • Business Wirelast year

    Bioasis Announces Filing of Its Quarterly Financial Statements and MD&A for the Period Ending May 31, 2018

    BIOASIS TECHNOLOGIES INC. , a biopharmaceutical company developing its xB3 TM proprietary platform technology for the delivery of therapeutics across the blood-brain barrier and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced that it has filed its unaudited quarterly financial statements and management’s discussion ...

  • Bioasis Welcomes John E. Curran & David M. Wurzer to the Company’s Board of Directors
    Business Wirelast year

    Bioasis Welcomes John E. Curran & David M. Wurzer to the Company’s Board of Directors

    Maha Radhakrishnan, M.D. has resigned as a director due to personal reasons